Monte Rosa prices $300M public offering of common stock and pre-funded warrants

Monte Rosa Therapeutics, Inc.

Offering of 11,125,000 shares at $24.00/share and pre-funded warrants for 1,375,000 shares at $23.9999 each.
Gross proceeds ~$300M; estimated net ~$281.6M after discounts and expenses.
Underwriters granted 30-day option to purchase up to 1,875,000 additional shares.
Proceeds to fund MRT-8102 for atherosclerotic cardiovascular disease, QuEEN platform development, and working capital.
Expects cash runway into 2029; closing expected on or about January 12, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Monte Rosa Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters valued at $24.00 per share (effective 2026-01-08).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters
Value: $24.00 per share
Effective: 2026-01-08

Exact text from the filing

On January 8, 2026, Monte Rosa Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”), related to an underwritten public offering (the “Offering”) of 11,125,000 shares (the “Underwritten Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a public offering price of $24.00 per share

View on SEC.gov

294 material agreements filed in the last 30 days. Browse all material agreements →

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-009005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.